drugset
drugset / Trial / NCT07603557

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

NCT07603557 ↗

Phase 2 Not yet recruiting 52 enrolled Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).

Timeline

Start
2026-08-31
Primary completion
2030-05-06
Completion
2030-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolacabtagene- Autoleucel Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

autoimmune hemolytic anemia autoimmune thrombocytopenia